Table 2 Baseline characteristics, intra-operative outcomes, and post-operative outcomes of those who had a reoperation due to infection versus those who did not.
All Patients | No Infection | Infection | p value | |
|---|---|---|---|---|
N (%) | 530 | 501 (94.5) | 29 (5.5) | |
Age, median (IQR) | 64 (58–68) | 64 (59–68) | 62 (58–67) | 0.41 |
BMI, median (IQR) | 28.4 (25.8–31.8) | 28.3 (25.8–31.7) | 29.1 (25.8–34.3) | 0.48 |
Race, N (%) | 0.25 | |||
Non-Hispanic White | 10 (1.9) | 9 (1.8) | 1 (3.4) | |
Non-Hispanic Black | 73 (13.9) | 66 (13.3) | 7 (24.1) | |
Hispanic | 365 (69.4) | 346 (69.6) | 19 (65.5) | |
Other | 78 (14.8) | 76 (15.3) | 2 (6.9) | |
Preferred Language, N (%) | 0.099 | |||
English | 171 (32.4) | 161 (32.3) | 10 (34.5) | |
Spanish | 354 (67.0) | 336 (67.3) | 18 (62.1) | |
Other | 3 (0.6) | 2 (0.4) | 1 (3.4) | |
Comorbidities, N (%) | ||||
Prostatectomy | 124 (23.4) | 120 (20.4) | 4 (13.8) | 0.21 |
XRT | 46 (8.7) | 43 (8.6) | 3 (10.3) | 0.74 |
Peyronie’s Disease | 31 (5.8) | 27 (5.4) | 4 (13.8) | 0.061 |
Sickle Cell/Priapism | 6 (1.1) | 5 (1.0) | 1 (3.4) | 0.23 |
Diabetes | 298 (56.2) | 281 (56.1) | 17 (58.6) | 0.79 |
Hemoglobin A1c, median (IQR) | 6.8 (5.8–8.1) | 6.8 (5.8–8.0) | 8.1 (6.8–8.5) | 0.039 |
Hypertension | 393 (74.2) | 365 (72.9) | 28 (96.6) | 0.005 |
Hyperlipidemia | 267 (50.4) | 253 (50.5) | 14 (48.3) | 0.82 |
Cardiac Disease | 124 (23.4) | 116 (23.2) | 8 (27.6) | 0.58 |
Chronic Kidney Disease | 77 (14.5) | 72 (14.4) | 5 (17.2) | 0.67 |
Smoker, N (%) | 0.006 | |||
Never | 336 (63.4) | 324 (64.7) | 12 (41.4) | |
Former | 154 (29.1) | 143 (28.5) | 11 (37.9) | |
Active | 40 (7.5) | 34 (6.8) | 6 (20.7) | |
Operative time (min), median (IQR) | 65 (55–79) | 64 (55–78) | 76 (55–86) | 0.18 |
Approach, N (%) | 0.038 | |||
Penoscrotal | 282 (53.2) | 272 (54.3) | 10 (34.5) | |
Infrapubic | 248 (46.8) | 229 (45.7) | 19 (65.5) | |
Concurrent Surgery, N (%) | ||||
Any | 141 (26.6) | 131 (26.1) | 10 (34.5) | 0.32 |
Circumcision | 102 (19.2) | 94 (18.8) | 8 (27.6) | 0.24 |
Penile Modeling | 44 (8.3) | 41 (8.2) | 3 (10.3) | 0.068 |
Other | 5 (0.9) | 4 (0.8) | 1 (3.4) | 0.15 |
Manufacturer, N (%) | 0.59 | |||
American Medical Systems | 30 (5.7) | 29 (5.8) | 1 (3.4) | |
Coloplast | 499 (94.3) | 471 (94.2) | 28 (96.6) | |
Implant Cylinder Size (cm), N (%) | 0.57 | |||
<18 | 55 (10.4) | 50 (10.0) | 5 (17.2) | |
18–19 | 191 (36.1) | 183 (36.6) | 8 (27.6) | |
20–21 | 192 (36.3) | 181 (36.2) | 11 (37.9) | |
22+ | 91 (17.2) | 86 (17.2) | 5 (17.2) | |
Reservoir Size ≥ 100cc, N (%) | 191 (36.4) | 182 (36.7) | 9 (31.0) | 0.54 |
Rear Tip Extender, N (%) | 266 (50.4) | 253 (50.7) | 13 (44.8) | 0.54 |
Surgical Drain, N (%) | 27 (5.1) | 25 (5.0) | 2 (6.9) | 0.65 |
EBL (cc), median (IQR) | 25 (15-50) | 25 (14-50) | 30 (23-50) | 0.29 |
Arista™ Powder Usage, N (%) | 176 (33.2) | 169 (33.7) | 7 (24.1) | 0.29 |
Discharged with catheter, N (%) | 45 (8.5) | 43 (8.6) | 2 (6.9) | 0.75 |
30-Day ED Presentation, N (%) | 65 (12.3) | 58 (11.6) | 7 (24.1) | 0.045 |
Pain/Swelling | 45 (71.4) | 43 (75.4) | 2 (33.3) | |
Retention | 10 (15.9) | 7 (12.3) | 3 (50.0) | |
Other | 8 (12.7) | 7 (12.3) | 1 (16.7) | |
